Member Info for Livedataaccount

Icecool, are you on another planet? Avacta released an RNS saying ava3396 will be in the clinic in 2023. They have form.

"a two-weekly dosing study, which is now screening patients with high FAP levels in the USA, will assist in optimising the schedule and dose for a Phase 2 study"

I take that as they are screening patients. The same as they said on December 13.

Surely you would say dosed if patients had been dosed.

Thanks Gracie, so 3 months on there has been no progress? I don't know how long screening takes.

And I just don't believe any projections made by Avacta.

That made me raise an eyebrow too.

Surely conifer have something to say about the way things have been run?

Has this even started yet? Or were they waiting for the fundraise to complete? They said they were screening patients early December? Is the consensus now that all news is secret squirrel for a while due to a US based investors taking part in the raise. But this of course could be fictional.

There has t been any TR1s so nobody has gone large on Avacta. Looks like will have to wait until the results day.

Dtw they also have 2 other trials in P1?

Avacta have been saying the will do the Ind for 3996 for years now.

To be fair market conditions are awful.

When money is incredibly tight at Avacta the unforgivable snafu by the CEO are recently splashing tens of millions on dx companies when every man and his dog knows tx is what matters at Avacta. Then due to having limited funds getting hammered by the market in this raise.

And even worse then spinning the notion he will sell of the dx companies so the company can carry on as a going corcern. Just a bonkers situation

Today

Timster, are you okay?

Sebastian has an interesting surname. Translates to grandad in English.

Have you though about getting a pet dog, Wyndrum?

Fair enough.

" AVA3996 has been selected as a candidate for preclinical development. Clinical Trial Authorisation (CTA) and/or Investigational New Drug (IND) filing expected H1 2023 and dosing of the first patient later in 2023."

The amount of RNS's that have contained statement that didn't materialise is ridiculous. Why is no one at Avacta accountable?

Interesting matml. All of this keeps bringing me back to why on earth did the CEO splash a whole heap of the bond fundraise on diagnostics businesses when the tx pipeline is well behind schedule?

I imagine there will be a bit of churn with some people flipping. Then its in everyone's interests for the SP to rise. Existing and new shareholders. The raise was significantly discounted as we all know. I'm expecting a decent rise into April and then with the P1 news at AACR this should anchor the share price.

This whole raise has been a shambles but worth reminding ourselves it was 20% dilution, so not huge.

It's up to Avacta now to manage some positive news flow.

You must be reading something I'm not. Dose expansions are part of a phase 1 trial.

From the 28 Feb RNS: "The dose expansions are expected to begin in H2 2024 in the USA, followed by the Phase 2 efficacy study, subject to funding and FDA approval, which the Board considers to be a major value-driving event for the Group. The dose expansions are expected to be in several orphan indications including soft tissue sarcomas and the selection of these dose expansion indications will be informed by data from the ongoing two-weekly and three-weekly dose escalation studies."

Surely, the Company has to clarify this?

If indeed it is 1b trial why are they not calling it that? It is industry standard, no?

And 3396 should be dosed by then. Although they have been forecasting filing the Ind for God knows how long now. So I would t bet my house on it.

One would hope Avacta would be well into phase 2 and some positive noises are coming from the company by that point.

"We can see that from the 1b phase (now named as "leading up to P2") that's reappeared in the (nonsense) timelines from nowhere (thanks for the comms Al)."

I am glad someone else has noticed that. AS should be pushed to clarify this in the next Q & A. Why he isn't calling it phase 1b? Like the rest of the pharma world would in a clinical trial. Unless 1B isnt happening and he could clarify this as there is some confusion.